How many stocks are there of Chimerix?
The current number of stocks of Chimerix is 88.6 M undefined.
Chimerix Stocks 2024
Chimerix Stocks
88.6 M
Ticker
CMRX
ISIN
US16934W1062
WKN
A1T65B
In 2024, Chimerix had 88.6 M outstanding stocks, a 0% change from the 88.6 M stocks in the previous year.
The Chimerix Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 88.6 |
| 2028e | 88.6 |
| 2027e | 88.6 |
| 2026e | 88.6 |
| 2025e | 88.6 |
| 2024e | 88.6 |
| 2023 | 88.6 |
| 2022 | 88.78 |
| 2021 | 84.93 |
| 2020 | 62.18 |
| 2019 | 55.5 |
| 2018 | 48.59 |
| 2017 | 46.96 |
| 2016 | 46.27 |
| 2015 | 43.88 |
| 2014 | 33 |
| 2013 | 19.31 |
| 2012 | 1.52 |
| 2011 | 1.5 |
| 2010 | 1.45 |
Chimerix shares outstanding US16934W1062 · A1T65B
The number of shares was Chimerix in 2023 — This indicates how many shares 88.604 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Chimerix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Chimerix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Chimerix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chimerix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2010 | 1.45 M Aktien |
| 2011 | 1.5 M Aktien |
| 2012 | 1.52 M Aktien |
| 2013 | 19.31 M Aktien |
| 2014 | 33 M Aktien |
| 2015 | 43.88 M Aktien |
| 2016 | 46.27 M Aktien |
| 2017 | 46.96 M Aktien |
| 2018 | 48.59 M Aktien |
| 2019 | 55.5 M Aktien |
| 2020 | 62.18 M Aktien |
| 2021 | 84.93 M Aktien |
| 2022 | 88.78 M Aktien |
| 2023 | 88.6 M Aktien |
| 2024e | 88.6 M Aktien |
| 2025e | 88.6 M Aktien |
| 2026e | 88.6 M Aktien |
| 2027e | 88.6 M Aktien |
| 2028e | 88.6 M Aktien |
| 2029e | 88.6 M Aktien |
Chimerix Aktienanalyse
What does Chimerix do?
Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Chimerix's Shares Outstanding
Chimerix's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Chimerix’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Chimerix’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Chimerix’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Chimerix Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Chimerix are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Chimerix evolved in recent years?
The number of shares of Chimerix has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Chimerix as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Chimerix?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Chimerix pay?
Over the past 12 months, Chimerix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chimerix is expected to pay a dividend of 0 USD.
What is the dividend yield of Chimerix?
The current dividend yield of Chimerix is .
When does Chimerix pay dividends?
Chimerix pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Chimerix?
Chimerix paid dividends every year for the past 0 years.
What is the dividend of Chimerix?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Chimerix located?
Chimerix is assigned to the 'Health' sector.
Wann musste ich die Aktien von Chimerix kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Chimerix from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.
When did Chimerix pay the last dividend?
The last dividend was paid out on 6/19/2024.
What was the dividend of Chimerix in the year 2023?
In the year 2023, Chimerix distributed 0 USD as dividends.
In which currency does Chimerix pay out the dividend?
The dividends of Chimerix are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Chimerix
Our stock analysis for Chimerix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chimerix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
